GLP-1 receptor agonists like semaglutide demonstrate bidirectional effects on skin biology through anti-inflammatory, immunometabolic, and tissue repair pathways. These medications may improve inflammatory conditions such as psoriasis and hidradenitis suppurativa while enhancing wound healing mechanisms. However, they're also associated with injection-site reactions, hypersensitivity eruptions, rare autoimmune blistering disorders, and clinically significant facial volume loss with skin laxity.
This finding represents a crucial paradigm shift in understanding GLP-1 medications beyond their metabolic effects. As millions now use these drugs for weight management, the skin implications become practically significant for aging adults. The facial deflation and skin laxity effects could paradoxically accelerate visible aging despite the drugs' potential longevity benefits through inflammation reduction. The mechanistic evidence suggests these aren't mere side effects but fundamental biological responses to GLP-1 pathway modulation. However, the review acknowledges that dermatology-specific randomized trials remain limited, meaning much evidence relies on observational signals rather than controlled studies. This knowledge gap is concerning given the widespread adoption of these medications and their potential long-term aesthetic consequences.